JP Morgan cuts FR, but options traders are piling into calls
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
First Industrial Realty Trust has been hit by five analyst target cuts in eight days, including a JP Morgan downgrade to Neutral from Overweight on Thursday with a new target of $60, down from $74. The stock has fallen 10.2% over the past month to $54.99. Yet options traders are moving sharply in the other direction.
Analysts in retreat
The cuts have come quickly and from across the Street. JP Morgan's Michael Mueller trimmed 19% from his target. Goldman Sachs's Caitlin Burrows cut from $72 to $62 on October 23. Raymond James downgraded to Outperform from Strong Buy, slashing the target from $86 to $71. Citigroup and Cantor Fitzgerald also lowered their targets, both settling at $60 and $58 respectively. The consensus mean now stands at $67.31, implying roughly 22% upside from the current price. Valuation concerns and sector pressure are the shared rationale.
Calls dominate despite the downgrades
The options market is reading the post-earnings selloff differently. The put/call ratio has collapsed to 0.11, nearly 2.3 standard deviations below its 20-day mean of 0.39. That compares to a 52-week PCR range of 0.0015 to 0.69. This is the most call-dominated reading in months. The shift is stark: through most of October the PCR sat between 0.42 and 0.49, consistent with a stock approaching a cautious earnings print. From October 27 onward, that flipped abruptly to the low 0.10s.
The earnings result on October 22 produced a one-day move of minus 8.4% and a five-day follow-through of minus 8.2%. The stock closed at $54.99 on October 29, up 1.2% on the day but still off 0.5% for the week. That compares to a median gain of roughly 0.1% among its closest peers: EGP fell 1.4%, while REXR gained 5.7% and STAG added 2.1%.
Short interest rises, borrow remains loose
Short interest has climbed 10.6% week-on-week to 4.2% of the free float, around 5.5 million shares, the highest level since late September. Over the past month the position is up 30%. The 90-day factor rank for days-to-cover sits at the 81st percentile. Despite the build, the borrow market is not signalling squeeze pressure. Availability is effectively unlimited, with over 113 million shares available against roughly 5.5 million short. Cost to borrow is 0.42%, up 11% on the week but still at the low end of its historical range.
The ORTEX short score stands at 39.1, and the analyst recommendation divergence factor ranks at the 99th percentile, reflecting how far the recent wave of downgrades has moved FR relative to prior consensus.
What to watch
The next earnings event is not until February 3, 2027. The immediate focus is whether the $60 level, which both JP Morgan and Citigroup have now set as their target, holds as a floor given the stock's current position at $54.99. A move back toward $60 would resolve the tension between the call-heavy options positioning and the wall of analyst downgrades bearing down on the stock.
Data summary
- Short interest: 4.2% of free float, up 10.6% week-on-week, up 30% month-on-month
- Put/call ratio: 0.11, z-score minus 2.3 vs. 20-day mean of 0.39
- Cost to borrow: 0.42%; availability effectively unlimited (113M+ shares available)
- Consensus price target: $67.31; stock at $54.99
- JP Morgan: downgraded to Neutral, target cut to $60 from $74 (minus 19%)
- Stock: minus 10.2% over 30 days; peers mixed, REXR plus 5.7%, EGP minus 1.4% on the week
Stocks in this article
See the live data behind this article on ORTEX.
Open FR on ORTEX →How this article was generated
- Generated
- 30 Oct 2026, 13:26
- Data as of
- 30 Oct 2026, 13:18
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesPrevious Mi Articles
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.